国家药监局：飞检发现一公司违反化妆品生产规定，药监部门已立案调查

Core Viewpoint - The National Medical Products Administration (NMPA) conducted a flight inspection of Anhui Teren Shake Biotechnology Co., Ltd., revealing serious deficiencies in the company's production quality management system, leading to a halt in production and an investigation by the Anhui Provincial Drug Administration [1][3]. Group 1: Inspection Findings - The company failed to effectively implement the sample management system and did not maintain sample records as required [2] - There were unauthorized changes to the functional area divisions of the production workshop [2] - The company did not effectively execute the material incoming inspection record system [2] - The production process did not adhere to the technical requirements specified in the filed documentation [2] Group 2: Regulatory Actions - The NMPA has mandated the Anhui Provincial Drug Administration to investigate the company's suspected illegal activities and assess the safety risks of related products, with emergency control measures to be taken if necessary [3] - The company is prohibited from resuming production until it completes comprehensive rectification and receives confirmation from the Anhui Provincial Drug Administration [3]